Initial results of the ongoing human clinical studies for the efficacy of TendoGuard, from Certified Nutraceuticals, Inc., has demonstrated positive clinical therapeutic value for connective tissue disorders and improved the mobility and activity for individuals with tendon/joint conditions.
 
For this study researchers chose 15 patients ages 17- 81 years (8 males / 7 females) with confirmed joint damage and cartilage injuries, diagnosed with imaging/scoping with low to high pain scales. The optimal dosage administered is 1500mg - 2500mg daily dietary supplement taken with citric juice on an empty stomach.
 
Supplementation with TendoGuard produced a significant treatment response at seven days for flexibility (29.6% increase; P = 0.036) and at 30 days for general pain (84.1% reduction; P = 0.006), flexibility (45.5% increase; P = 0.005), and range of motion associated pain (74.7% reduction; P = 0.020). The substantial treatment response continued through 30 days for pain (68.3% reduction; P = 0.0001). There were no adverse events reported during the study. Salivary pH tracking found that supplementation with TendoGuard reduced inflammation after 30 days.
 
These initial findings suggest that TendoGuard, when taken at a dosage of 375mg – 500mg twice per day, benefits joint inflammation, secondary mobility and other tertiary effects. The ingredientnaturally contains anti-inflammatory compounds and aids in the support of joint and/or tendon abnormalities, and systemically works to retain and preserve healthy structure anatomical placements namely tendon, bone, joint, cartilaginous structures. This study demonstrates that TendoGuard may be a viable treatment option for the management of joint and connective tissue disorders.
 
For more information: www.certifiednutra.com